On October 1, 2013, Actavis (NYSE: ACT) announced the acquisition of Warner Chilcott plc, creating an $11 billion leading specialty pharmaceutical company with over $3 billion in pro forma sales. The combination capitalizes on the complementary specialty pharmaceuticals strengths and market positions of the two organizations, building a leader in Women’s Health and Urology, as well as a company with important positions in Gastroenterology and Dermatology.
Warner Chilcott will be integrated within Actavis’ Specialty Brands division, a global branded specialty pharmaceutical business focused principally in the Women's Health and Urology therapeutic categories, as well as Gastroenterology and Dermatology in the United States. Internationally, Actavis Specialty Brands is focused on expanding its business in Canada and Latin America, and pursuing opportunities to expand in other key markets.
Actavis is also pursuing a strategy to build a leadership position in biosimilars, which includes a collaboration with Amgen to develop and commercialize, on a worldwide basis, biosimilar versions of Herceptin®, Avastin®, Rituxan/Mab Thera®, and Erbitux®. These products represent some of the fastest-growing pharmaceutical products in the world, with peak innovator sales topping $20 billion. Actavis expects the collaboration to launch its first biosimilar products beginning in 2017.
The Amgen/Actavis collaboration is in addition to Actavis’ ongoing efforts to develop and commercialize Itero Biopharmaceuticals, Inc.’s recombinant follicle stimulating hormone (rFSH) product as a biosimilar molecule for the treatment of female infertility.
For more information, visit www.Actavis.com
Warner Chilcott France
revendique dans ses pratiques un respect des principes éthiques et veille à être exemplaire dans la mise en œuvre de ces engagements.
Currently, Warner Chilcott's marketed products are concentrated in four therapeutic categories: gastroenterology, women's health, dermatology and urology.
ASACOL® is the leading treatment for ulcerative colitis in the U.S. market for orally administered 5-aminosalicylic acid products. The new delayed-release formulation ASACOL® HD provides dosing advantages for patients in the treatment of moderately active ulcerative colitis.
ACTONEL® is the leading branded product in the U.S. non-injectable osteoporosis market for the prevention and treatment of osteoporosis in women.
LOESTRIN® 24 Fe was the first oral contraceptive featuring 24 days of active therapy compared with the traditional 21-day dosing regimen. The Company's oral contraceptive portfolio also includes FEMCON® Fe, OVCON® 35 and OVCON® 50 and ESTROSTEP® Fe.
ESTRACE® Cream is a leading topical product for the treatment of urogenital symptoms of menopause.
FEMHRT® is a systemic therapy for the treatment of menopausal symptoms.
DORYX® 150 mg, a tetracycline-class oral antibiotic, is indicated for the adjunctive treatment of severe acne. DORYX is one of the leading branded oral tetracyclines in the U.S. market.
ENABLEX® is prescribed to adults to treat the symptoms of overactive bladder.
The Company's internal development efforts are focused primarily on developing new products that target therapeutic areas with established regulatory guidance. Warner Chilcott seeks to leverage the experience and proven capabilities of its research and development team to make proprietary improvements to its existing products, develop new and enhanced dosage forms and bring new products to market. This group of talented professionals possesses expertise in chemistry, formulation, clinical operations, and the regulatory approval processes in the U.S. and Western Europe. Its efforts have produced a number of successful internally developed products launched during the last several years.
To supplement its organic growth, Warner Chilcott continually evaluates opportunities to expand its pharmaceutical product portfolio by reviewing potential product in-licensing, acquisition and partnership opportunities that it believes will complement its strategic focus and that may benefit from promotion by its sales force. Examples of the pursuit of this strategy include Warner Chilcott's product development relationships with Paratek Pharmaceuticals, Inc. and Dong-A PharmTech Co. Ltd.
Warner Chilcott will consider requests for support from organizations that fit with its business focus and policy considerations, and that fall within the following therapeutic areas and categories:
- Women’s healthcare
Please review the submission instructions (US
) prior to applying for a grant.